Aim: To investigate the impact of oxaliplatin resistance on the cellular characteristics and miRNA expression pattern in colorectal cancer cells. Methods: A stable oxaliplatin-resistant colorectal cancer HCT116 cell line was established by exposure to increasing doses of oxaliplatin. Alterations in cytotoxicity, migration, invasion and tumorsphere formation were assessed by MTS assay, modified Boyden chamber assay, and colonosphere assay respectively. The miRNAome of the oxaliplatin-resistant HCT116 cells was analyzed using the TaqMan PCR Human miRNA array. Upregulated miRNAs from the PCR array were validated by real-time reverse transcription-quantitative PCR (RT-qPCR). Results: Oxaliplatin-resistant HCT116 cells exhibited higher migration, invasion and tumorsphere formation compared to parental oxaliplatin-sensitive HCT116 cells. The oxaliplatin-resistant cells showed a distinct miRNA expression profile compared to the parental cells. The expression of miR-601, miR-222, miR-202 and miR-25 were verified by RT-qPCR to be increased in resistant cells. Bioinformatics analyses were used to identify potential target mRNAs of these 4 miRNAs. Conclusion: Results presented in this study provide evidence that oxaliplatin-resistance induces phenotypic changes in colorectal cancer and alterations in miRNA expression. Functional studies on the miRNAs and their target mRNA may enable the discovery of functional pathways to chemoresistance in colorectal cancer.
Introduction
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death worldwide [1] . First line chemotherapy for metastatic CRC includes the combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI), fluorouracil, leucovorin, and oxaliplatin (FOLFOX), capecitabine and oxaliplatin (XELOX), and the combination of fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) [2] . The use of these combination therapies for metastatic CRC have led to response rates of >50% and median survival of up to 2 years [3, 4] . However, practically all metastatic CRC become resistant to chemotherapy [5] .
Oxaliplatin is a third-generation platinum compound that forms DNA adducts and induces cellular apoptosis [6] . Resistance mechanisms reported for oxaliplatin include increased nucleotide
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International Publisher excision repair of DNA lesions e.g., mediated by ERCC1 [7] ; however no biomarkers of oxaliplatin resistance have been identified to sub-classify CRC patients for selection of chemotherapy. Therefore it is important to discover the molecular mechanisms and associated biomarkers of resistance to identify patients who are unlikely to respond to oxaliplatin but also to develop new treatments to overcome oxaliplatin resistance.
MicroRNAs (miRNAs) are small (18-25 nucleotides), noncoding RNAs that regulate the expression of their target genes by inhibiting translation or cleaving messenger RNA (mRNA), through interaction with the 3' untranslated regions (UTRs) of the target mRNAs [8] . MiRNAs can simultaneously regulate multiple targets and biological networks, and several miRNAs can cooperatively regulate a single mRNA target [8] . Expression profiling of human tumors has identified miRNA signatures associated with diagnosis, progression, prognosis and response to treatment [9] .
There are several lines of evidence for the importance of miRNAs in regulating biological processes related to the sensitivity of tumor cells to chemotherapeutic drugs [10] . Multiple signaling networks have been suggested to collectively provide a plausible mechanism for chemotherapy resistance, cancer stem cell survival, invasiveness and metastases [11] . Because of the pleiotropic roles of miRNA in signaling networks, we hypothesize that miRNAs are involved in the cellular alterations that occur during the process of chemoresistance acquisition. To test this hypothesis, we developed an oxaliplatin-resistant HCT116 colorectal cancer cell line from the parental chemosensitive HCT116 cell, investigated the cellular alterations, and performed high throughput miRNA expression profiling to identify miRNAs associated with chemoresistance.
Materials and Methods

Generation of resistant cell line
HCT116 human colon carcinoma cells were obtained from the American Type Culture Collection. The cells were cultured in McCoy's 5A Medium (Lonza, Switzerland) supplemented with 10% fetal bovine serum (Gibco®, USA) and 2mM glutamine (Lonza, Switzerland) at 37°C in 5% CO2. Oxaliplatin (5 mg/ml) was obtained from the National University Hospital Singapore pharmacy and stored at 4°C protected from light. The oxaliplatin resistant HCT116 cell line was generated in our laboratory by exposing parental HCT116 cells to an initial concentration of 2 µM oxaliplatin and culturing the surviving cells to a confluency of 80% over 2 passages. The surviving cells were then exposed to gradually increasing concentrations of oxaliplatin from 3 µM to 6 µM over a period of 90 days. The cell lines were passaged 2 times at each concentration and cell vials were frozen at each increase in concentration. The oxaliplatin resistant cells were cultured in McCoy's 5A Medium supplemented with 10% fetal bovine serum and 2mM glutamine at 37°C in 5% CO2 and maintained by adding 6 µM oxaliplatin at every 2 passages.
Chemosensitivity assay
In vitro drug sensitivity was determined using the Promega Cell Proliferation MTS Assay (Promega, Madison, WI, USA). SN-38 (Sigma-Aldrich, USA) was dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C. 5-fluorouracil (5-FU) (50 mg/ml) was obtained from the National University Hospital Singapore pharmacy and stored at room temperature (25°C) protected from light. Cells were seeded in 96-well plates at a density of 5 X 10 3 per well and a range of drug concentrations of oxaliplatin or SN-38 were added the following day. Following 72 h of drug exposure, the medium was changed and the cells were incubated with 20 µl of MTS solution for 1 h. Absorbance at 492 nm was measured and the cell viability was compared in percent to untreated cells. The experiment was performed in triplicates and the mean cell viability ± standard deviation was determined. The concentration of drug resulting in 50% inhibition of control growth (IC50) was calculated. Comparison between the parental and resistant cell lines was done using unpaired Student's t-test (p < 0.05 considered significant).
Migration assay
Cell migration was assessed using ibidi culture inserts (ibidi, GmbH, Denmark). An ibidi culture insert was placed into a well of a 24-well plate (Corning, USA) and lightly pressed to ensure tight adhesion. Cells were plated at a concentration of 1 X 10 5 cells per ml, and after 24 h of incubation, culture inserts were removed, leaving behind a 500 µm-wide cell-free gap. The medium was changed to McCoy's 5A Medium with 2% fetal bovine serum and photographs of the movement of the cells into the cell-free gap were taken every 24 h until the gap had closed using a Nikon light microscope. The quantitative values of the gap size were calculated using the web-based WimScratch module of Wimasis online software [12] . The experiment was performed three times and the mean wound area ± standard deviation was determined. Comparison between the parental and resistant cell lines was done using unpaired Student's t-test (p < 0.05 considered significant).
Invasion assay
Cell invasion was assessed using ECMatrix Cell Invasion Assay (Millipore, USA). Cells were resuspended in McCoy's 5A Medium to 5 X 10 4 cells in the upper well of the Transwell migration chamber (Millipore, USA). McCoy's 5A Medium with 10% fetal bovine serum was placed in the lower well as a chemoattractant. After 24 h, the upper wells were removed and the cells in the lower wells were stained with hematoxylin and photographed using a Nikon light microscope. The area covered by the cells was quantitated using Adobe Photoshop. The experiment was performed three times and the mean cell area ± standard deviation was determined. Comparison between the parental and resistant cell lines was done using unpaired Student's t-test (p < 0.05 considered significant).
Sphere formation assay
Cells were plated at 1000 cells per well in 24-well ultralow attachment plates (Corning, USA) in stem cell medium. Stem cell medium consisted of 70% McCoy's 5A Medium, 30% Ham's F-12 Medium (Lonza), B-27 supplement (ThermoFisher, USA), 10% penicillin/streptomycin, 1% methylcellulose, epidermal growth factor (EGF; 10 ng/ml) and basic fibroblast growth factor (bFGF; 10 ng/ml). After 8 days, the wells were photographed using a Nikon light microscope. The area covered by the cells was quantitated using Adobe Photoshop. The experiment was performed three times and the mean sphere area ± standard deviation was determined. Comparison between the parental and resistant cell lines was done using unpaired Student's t-test (p < 0.05 considered significant).
RNA extraction
Total RNA was extracted from each cell line using the Taqman® Gene Expression Cells-to-CT™ Kit (Thermo Fisher Scientific, USA) according to the manufacturer's instruction. RNA concentration and quality were determined using a NanoDrop 8000 UV-Vis spectrophotometer (Thermo Fisher Scientific, USA).
MiRNA expression profiling using TaqMan array
MiRNA expression profiling was performed using TaqMan® Array Human MiRNA Card Set v3.0, a preconfigured 2-microfluidic card set (A and B) containing 754 unique assays specific to human miRNAs (Thermo Fisher Scientific, USA). MiRNA was reversed transcribed using the miRNA reverse transcription kit (Applied Biosystems) combined with the Megaplex Primer Pools A and B according to the manufacturer's protocol. Preamplification was performed using the Megaplex PreAmp Primers Human Pool Set v3.0 (Thermo Fisher Scientific, USA) according to the manufacturer's protocol. The pre-amplification product was diluted in Tris-EDTA buffer, mixed with TaqMan Universal PCR Master Mix No AmpErase UNG (Life Technologies), and loaded into the Microfluidic Array Cards according to the manufacturer's instruction. PCR reactions were performed on the QuantStudio™ 12K Flex Real-Time PCR system. Data from the TaqMan® Human Array MiRNA Cards were analyzed using DataAssist™ Software v1.0 (ThermoFisher Scientific) and the data was normalized using the global normalization function [13] .
MiRNA quantitative real-time PCR
Selected miRNAs identified by the TaqMan® Human MiRNA Array were validated with reverse transcription (RT) -quantitative real-time PCR (RT-qPCR). MiRNA RT-qPCR was performed using IDEAL miRNA assays (MiRXES, Singapore) [14] , according to the manufacturer's protocol. The real-time PCR assay was performed using the QuantStudio™ 12K Flex Real-Time PCR system. The relative miRNA expression was calculated using the comparative Cq method (fold change = 2 -ΔΔ Cq ) [15] . The fold change of miRNA expression of the resistant cell line was expressed relative to that of the parental cell line. The experiment was performed three times and the mean relative fold change ± standard deviation was determined. Comparison between the parental and resistant cell lines was done using unpaired Student's t-test (p < 0.05 considered significant).
In silico analyses of potential mRNA targets
Potential mRNA targets of the candidate miRNAs were obtained from miRTarBase (last accessed 10 Feb 2017) [16] . Potential mRNA targets were analyzed using the DAVID functional annotation tool (last accessed 10 Feb 2017) [17, 18] by KEGG pathway.
Results
Generation and phenotypic characterization of oxaliplatin-resistant HCT116 human colorectal cells
The oxaliplatin-resistant HCT116 cell line was generated by exposing the sensitive parental cell line to increasing concentrations of oxaliplatin from 2 µM to 6 µM over a period of 3-4 months. Drug sensitivities towards oxaliplatin and SN-38, the active metabolite of irinotecan, were measured for each cell line (Fig. 1) . Parental HCT116 cells were significantly more sensitive to oxaliplatin at 2 and 5 µM compared to the resistant HCT116 cells (p < 0.001) (Fig. 1) . The IC50 of oxaliplatin-resistant cells and parental cells for oxaliplatin were calculated to be 10 µM and 5 µM respectively. Parental HCT116 cells also appeared more sensitive to SN-38 at 2 and 5 nM, compared to the resistant HCT116 cells (p < 0.05) (Fig. 1) . The IC50 of oxaliplatin-resistant cells and parental cells for SN-38 were 10 nM and 7 nM respectively. There was no difference in sensitivity to 5-FU at 2 and 5 µM between the oxaliplatin-resistant and the parental HCT116 cells (Fig. 1) . The IC50 was 13.5 µM for both the oxaliplatin-resistant cells and parental cells for 5-FU.
Previous studies have shown that acquired drug resistance can facilitate invasion and migration of colorectal cancer cells [19] , therefore we compared the migratory and invasive capacities of the resistant HCT116 cells to the parental HCT116 cells. Resistant HCT116 cells exhibited an increased migratory rate compared to parental HCT116 cells (p < 0.001) (Fig.  2A) . Resistant HCT116 cells also exhibited an increased capacity to invade compared to the parental HCT116 cells (p < 0.001) (Fig. 2B) . Cancer stem cells (CSCs) have the ability to form colonies, or spheres, in the absence of serum without attachment to culture plates [20] . We evaluated the ability of the resistant and parental HCT116 cells to grow colon cancer cell spheres under serum-free conditions. Oxaliplatin-resistant HCT116 cells showed an increased ability to form spheres compared to parental HCT116 cells (p < 0.001) (Fig. 2C) .
MiRNA profiling of oxaliplatin-resistant HCT116 cells
To identify the molecular alterations responsible for the drug resistance phenotype, miRNA expression profile of the oxaliplatin-resistant cells was compared with the parental cells using TaqMan Array Human MiRNA Cards containing 754 human miRNA assays. The array for the oxaliplatin-resistant cells was performed in duplicates and the duplicates showed good correlation with each other (Fig. 3) . The miRNA profiles were compared between the resistant and parental cells, and 55 significantly upregulated miRNA in the resistant cell line were identified (Fig.  3) . In addition, a further 22 miRNA were significantly downregulated in the resistant cell line compared to the parental cell line (Fig. 4) . More miRNAs were upregulated than downregulated in the resistant cell line, suggesting that upregulation of miRNAs, resulting in downregulation of oncogenes, may be the dominant pathway in chemoresistance. 
Validation of miRNA expression by RT-qPCR
To independently validate the differential expression of miRNAs identified by the TaqMan Array, we chose 24 candidate overexpressed miRNAs (miR-15b, miR-19a, miR-100-3p, miR-106a, miR-106b-3p, miR-125b, miR-126, miR-135b-3p, miR-139-5p, miR-185, miR-192, miR-193a-5p, miR-196b, miR-202, miR-215, miR-222, miR-25, miR-30a, miR-30d, miR-324-5p, miR-584, miR-601, miR-639, miR-744-5p) for RT-qPCR analysis. We found that the expression of 4 miRNAs (miR-601, miR-222, miR-202, and miR-25) were significantly different (p <0.05) between the resistant and parental cell lines (Fig. 5) .
In silico analyses of potential mRNA targets
We further collected experimentally known target mRNAs of the 4 miRNAs from miRTarBase and used the DAVID functional annotation tool to perform pathway analysis on the target mRNAs. The top KEGG pathways identified were pathways in cancer and cell cycle, suggesting that these pathways may be important in chemoresistance acquisition. Out of 263 possible targets, 22 target genes were in pathways in cancer and 13 were in the cell cycle pathway (Fig. 6) . 
Discussion
Acquisition of resistance to chemotherapeutic agents is one of the main problems in cancer treatment. In this study we focused on oxaliplatin resistance in colorectal cancer. We assessed the migratory and invasive ability of the HCT116 colorectal cell line with acquired resistance to oxaliplatin and its parental line. Our observations suggest that resistance acquisition is associated with increased invasive and migratory capacity, indicating increased metastasis ability. Oxaliplatin-resistant HT29 and KM12L4 colorectal cells were also observed to undergo epithelial-mesenchymal transition (EMT) to acquire a more invasive and migratory phenotype by Yang et al. [19] . EMT is a process through which cells switch from an epithelial state to a more primitive mesenchymal state to facilitate invasion and migration [20] . The chemoresistance-induced migratory and invasive phenotype observed suggests that chemoresistant cancer cells may be better able to form metastases, and that targeting the process of EMT could aid in reversing chemoresistance.
We observed an increased ability of the oxaliplatin-resistant HCT116 cells to form spheres under serum-free conditions, suggesting an enrichment of CSCs induced by the acquisition of chemoresistance. Oxaliplatin-resistant HT29 cells were also observed to acquire a CSC phenotype by Dallas et al. [21] . CSCs are cells with indefinite potential for self-renewal to drive tumorigenesis [22] . Tumor cells that are resistant to chemotherapy may represent a subpopulation of cells from the original tumor, commonly referred to as CSCs [23] . The CSC phenotype observed in the oxaliplatin-resistant cells suggests that similar molecular mechanisms may be involved in resistance acquisition and transformation to CSCs.
In this study we comprehensively profiled the expression of 754 human miRNAs in the resistant and parental cell line. Out of 754 miRNAs, 55 showed upregulated expression in the resistant cells compared to the parental cell line. The upregulation of multiple miRNAs in the resistant cells suggests that multiple complex molecular processes are involved in the acquisition of resistance. Of the 55 miRNAs, 24 miRNAs were validated by RT-qPCR and 4 (miR-601, miR-222, miR-202, and miR-25) were found to be significantly upregulated in the oxaliplatin-resistant cell line compared to the parental cells. The most highly upregulated miRNA, miR-601, had been observed to be downregulated in the plasma of colorectal cancer patients compared to healthy controls [24] . The expression of miR-601 was also found to be downregulated in breast cancer tissues compared to adjacent non-cancerous breast tissues overexpression of miR-601 suppressed breast cancer cell migration and invasion [25] . These findings appear to suggest a role for miR-601 as a tumor suppressor and a biomarker for good prognosis, which is in contrast to our observations in the oxaliplatin-resistant HCT116 cells. Widespread context dependency of miRNA-mediated regulation has been described [26] , therefore it is possible that the differences between our observations and other studies for the role of miR-601 in cancer may be context dependent. Global profiling of the molecular pathways regulated by miR-601 identified multiple pathways including upregulation of actin cytoskeleton, downregulation of Fas-induced apoptotic pathway, and downregulation of NF-kappaB expression [27] . Upregulation of the actin cytoskeleton may play a role in increased invasiveness and migratory capacity observed in the resistant cells, while downregulation of apoptosis may play a role in resistance to apoptotic pathways triggered by oxaliplatin-induced DNA damage.
MiR-222 has been previously identified to be involved in oxaliplatin resistance in colorectal cancer [28] . The downstream target pathways involved in platinum-based anti-cancer drugs may include the Akt-mTOR pathway [29] and the ATP-binding cassette (ABC) transporter, ABCG2 [30] .
Pathak et al. found that miR-202 was upregulated in HCT116 p53+/+ cells after radiation treatment [31] . However, Wang et al. showed downregulation of miR-202 in colorectal cancer tissues compared to non-cancerous tissues and suggested that miR-202 may function as a tumor suppressor by suppressing cell proliferation [32] . Decreased cell proliferation has been associated with an increase in chemoresistance through miR-215 [33] , therefore reduced cell proliferation and resistance acquisition may share common molecular pathways.
Neerincx et al. found that miR-25 is highly expressed in colorectal cancer and their metastases by next-generation sequencing [34] . Furthermore, miR-25 was shown to enhance cell proliferation, migration and invasion of gastric cancer cells [35] . However, ovarian cancer non-responders to carboplatin therapy were shown to have decreased levels of miR-25 [36] . In addition, mir-25 was found to be downregulated in cisplatin-resistant cervical cancer cells and overexpression of mir-25 reversed the EMT phenotype of the cisplatin-resistant cervical cancer cells [37] . MiRNAs can influence drug resistance not only in a drug-specific manner but also in a cell-specific manner [38] . Perhaps the opposing roles for mir-25 observed in these studies relative to our observations may be due to cell-specific and/or drug-specific effects.
It would be necessary to confirm that the miRNAs that are upregulated are responsible for the increased invasive and stem cell formation phenotypes observed. A limitation of this study is that only one cell line was studied. Jensen et al. profiled the transcriptome of 3 different colorectal cancer oxaliplatin-and irinotecan-resistant cell lines and found that each cell line had a distinctive resistance gene expression profile [39] . Therefore the molecular alterations observed in the oxaliplatin-resistant HCT116 cells may not be generalizable to all colorectal cancers. Another limitation of this study is that no in vivo surgically resected human colorectal cancer tissue samples were studied. Therefore, our findings need to be interpreted with caution when extrapolating clinical relevance from cell line data. Because of this limitation, the usefulness of this study is limited to an exploratory, hypothesis-generating analysis rather than an endpoint analysis.
In conclusion, this study identified several candidate miRNAs that may be involved in the mechanism of acquisition of resistance to oxaliplatin. Functional studies on the miRNAs and their target mRNA are necessary to discover the functional pathways to chemoresistance in colorectal cancer.
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